Privia Health Signs Agreement with NGBC to Enter New Jersey
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Privia Health announced it has signed a definitive agreement to enter the state of New Jersey in partnership with Neurology Group of Bergen County, or NGBC, a practice with 25 adult and pediatric clinicians. NGBC will serve as the anchor practice for Privia Medical Group-New Jersey and is expected to be implemented on the Privia Platform by year-end 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRVA
Wall Street analysts forecast PRVA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.590
Low
23.00
Averages
30.40
High
34.00
Current: 21.590
Low
23.00
Averages
30.40
High
34.00
About PRVA
Privia Health Group, Inc. is a technology-driven, national physician-enablement company. The Company collaborates with medical groups, health plans and health systems. It enhances physician practices, improves patient experiences and doctors for delivering care in both in-person and virtual care settings. Its Privia Platform is powered by the Privia Technology Solution, an end-to-end, cloud-based technology solution that integrates both Privia-developed and third-party applications into an interface and workflow that manages all aspects of its Privia Providers provision of healthcare services. Privia Platform optimizes provider workflow across the full continuum of reimbursement arrangements. The Company provides management services to each Medical Group though a local management services organization, which provides Medical Groups with access to value-based care (VBC) opportunities either directly or through Privia-owned accountable care organizations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rubicon Founders Increases Stake in Privia Health Group
- Increased Holdings: Rubicon Founders purchased an additional 175,142 shares of Privia Health Group in Q1 2026, with an estimated trade value of $3.95 million, indicating a strong bullish sentiment as this stock now constitutes 88.92% of the fund's reportable AUM.
- Strong Financial Performance: Privia Health Group reported $2.1 billion in revenue for 2025, marking a 22% year-over-year increase, while net income surged 59% to $22.9 million, reflecting robust market demand and profitability in the healthcare sector.
- Healthy Balance Sheet: As of 2025, Privia Health's total assets stood at $1.4 billion against total liabilities of $578.4 million, with no debt, showcasing a solid financial position that supports future growth initiatives.
- Optimistic Future Outlook: In Q1 2026, Privia Health's revenue rose 26% year-over-year, with full-year projections estimating around $2.4 billion, indicating that its solutions are effectively addressing unmet needs in the healthcare industry, thus presenting significant long-term investment potential.
See More
Rubicon Founders Increases Stake in Privia Health Group
- Increased Holdings: Rubicon Founders LLC increased its stake in Privia Health Group by 175,142 shares in Q1 2026, with an estimated transaction value of $3.95 million, indicating a bullish outlook as the stock now represents 88.92% of its 13F reportable AUM.
- Financial Performance: Privia Health reported a 22% year-over-year revenue growth in 2025, reaching $2.1 billion, with net income rising 59% to $22.9 million, showcasing its strong market position and demand for its services in the healthcare sector.
- Market Expectations: In Q1 2026, Privia Health's revenue grew 26% year-over-year to $603.8 million, with full-year revenue projected to reach around $2.4 billion, indicating that its solutions are addressing unmet needs in the healthcare industry and boding well for future success.
- Investment Value: The increase in holdings by Rubicon Founders positions Privia Health's stock as a core asset in its portfolio, reflecting a positive long-term investment outlook that may attract further investor interest.
See More
Privia Health Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Privia Health reported a Q1 non-GAAP EPS of $0.19, missing expectations by $0.06, while revenue reached $603 million, reflecting a 25.6% year-over-year increase and exceeding estimates by $41.07 million, indicating strong market performance.
- Guidance Update for 2026: The company maintained its full-year 2026 outlook for most metrics, raising the guidance range for Attributed Lives to between 1.6 million and 1.625 million, showcasing confidence in future growth prospects.
- Operational Efficiency Improvement: It is expected that approximately 80% of Adjusted EBITDA will convert to free cash flow in 2026, enhancing the company's financial flexibility and supporting future investments.
- Market Expansion Plans: Privia Health targets a 19.5% growth in Adjusted EBITDA for 2026 while expanding its footprint to 24 states, further solidifying its competitive position in the national market.
See More
Privia Health (PRVA.US) Director Plans to Sell $40.47 Million in Common Stock via Form 144
Share Sale Announcement: Matthew Shawn Morris intends to sell 1.63 million shares of Privia Health (PRVA.US) on May 1, with a total market value of approximately $40.47 million.
Reduction in Shareholding: Since February 26, 2026, Morris has reduced his shareholding in Privia Health by 24,338 shares, valued at approximately $608.36K.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Executive Stock Sale: David Mountcastle, CFO of Privia Health, sold 13,018 shares between March 12 and 13, 2026, for approximately $283,000 at an average price of $21.71 per share, representing 5.24% of his total direct holdings.
- Tax Obligation Reason: The sale was strictly for tax withholding obligations related to the vesting of performance stock units, indicating that investors should not interpret this transaction as a negative signal for PRVA stock, but rather focus on the company's fundamentals.
- Strong Financial Performance: Despite a 10% decline in PRVA's stock price in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting 7 cents per share, surpassing the 4-cent estimate and marking the highest year-over-year growth since Q3 2023.
- Market Expansion Potential: Privia's acquisition of an Accountable Care Organization in late September 2025 added approximately 1.5 million customers, showcasing the company's growth potential in value-based operations, although analysts remain cautious about its future performance.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Transaction Overview: Privia Health CFO David Mountcastle sold 13,018 shares on March 12 and 13, 2026, for approximately $283,000, indicating a necessary action for tax obligations related to stock vesting.
- Ownership Percentage Change: This transaction reduced Mountcastle's direct holdings by 5.24%, leaving him with 226,804 shares directly held, which represents a 0.18% stake in the company's outstanding shares, reflecting changes in ownership structure.
- Stable Financial Performance: Despite a 10.15% decline in PRVA stock in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting earnings of $0.07 per share, significantly above the $0.04 estimate, demonstrating resilience in its fundamentals.
- Customer Base Expansion: By acquiring an Accountable Care Organization (ACO), Privia gained approximately 1.5 million customers with medical plans such as Medicare, Medicare Advantage, and Medicaid, indicating growth potential in its value-based operations.
See More
Rubicon Founders Increases Stake in Privia Health Group
- Increased Holdings: Rubicon Founders purchased an additional 175,142 shares of Privia Health Group in Q1 2026, with an estimated trade value of $3.95 million, indicating a strong bullish sentiment as this stock now constitutes 88.92% of the fund's reportable AUM.
- Strong Financial Performance: Privia Health Group reported $2.1 billion in revenue for 2025, marking a 22% year-over-year increase, while net income surged 59% to $22.9 million, reflecting robust market demand and profitability in the healthcare sector.
- Healthy Balance Sheet: As of 2025, Privia Health's total assets stood at $1.4 billion against total liabilities of $578.4 million, with no debt, showcasing a solid financial position that supports future growth initiatives.
- Optimistic Future Outlook: In Q1 2026, Privia Health's revenue rose 26% year-over-year, with full-year projections estimating around $2.4 billion, indicating that its solutions are effectively addressing unmet needs in the healthcare industry, thus presenting significant long-term investment potential.
See More
Rubicon Founders Increases Stake in Privia Health Group
- Increased Holdings: Rubicon Founders LLC increased its stake in Privia Health Group by 175,142 shares in Q1 2026, with an estimated transaction value of $3.95 million, indicating a bullish outlook as the stock now represents 88.92% of its 13F reportable AUM.
- Financial Performance: Privia Health reported a 22% year-over-year revenue growth in 2025, reaching $2.1 billion, with net income rising 59% to $22.9 million, showcasing its strong market position and demand for its services in the healthcare sector.
- Market Expectations: In Q1 2026, Privia Health's revenue grew 26% year-over-year to $603.8 million, with full-year revenue projected to reach around $2.4 billion, indicating that its solutions are addressing unmet needs in the healthcare industry and boding well for future success.
- Investment Value: The increase in holdings by Rubicon Founders positions Privia Health's stock as a core asset in its portfolio, reflecting a positive long-term investment outlook that may attract further investor interest.
See More
Privia Health Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Privia Health reported a Q1 non-GAAP EPS of $0.19, missing expectations by $0.06, while revenue reached $603 million, reflecting a 25.6% year-over-year increase and exceeding estimates by $41.07 million, indicating strong market performance.
- Guidance Update for 2026: The company maintained its full-year 2026 outlook for most metrics, raising the guidance range for Attributed Lives to between 1.6 million and 1.625 million, showcasing confidence in future growth prospects.
- Operational Efficiency Improvement: It is expected that approximately 80% of Adjusted EBITDA will convert to free cash flow in 2026, enhancing the company's financial flexibility and supporting future investments.
- Market Expansion Plans: Privia Health targets a 19.5% growth in Adjusted EBITDA for 2026 while expanding its footprint to 24 states, further solidifying its competitive position in the national market.
See More
Privia Health (PRVA.US) Director Plans to Sell $40.47 Million in Common Stock via Form 144
Share Sale Announcement: Matthew Shawn Morris intends to sell 1.63 million shares of Privia Health (PRVA.US) on May 1, with a total market value of approximately $40.47 million.
Reduction in Shareholding: Since February 26, 2026, Morris has reduced his shareholding in Privia Health by 24,338 shares, valued at approximately $608.36K.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Executive Stock Sale: David Mountcastle, CFO of Privia Health, sold 13,018 shares between March 12 and 13, 2026, for approximately $283,000 at an average price of $21.71 per share, representing 5.24% of his total direct holdings.
- Tax Obligation Reason: The sale was strictly for tax withholding obligations related to the vesting of performance stock units, indicating that investors should not interpret this transaction as a negative signal for PRVA stock, but rather focus on the company's fundamentals.
- Strong Financial Performance: Despite a 10% decline in PRVA's stock price in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting 7 cents per share, surpassing the 4-cent estimate and marking the highest year-over-year growth since Q3 2023.
- Market Expansion Potential: Privia's acquisition of an Accountable Care Organization in late September 2025 added approximately 1.5 million customers, showcasing the company's growth potential in value-based operations, although analysts remain cautious about its future performance.
See More
Privia Health CFO Sells Shares for Tax Obligations
- Transaction Overview: Privia Health CFO David Mountcastle sold 13,018 shares on March 12 and 13, 2026, for approximately $283,000, indicating a necessary action for tax obligations related to stock vesting.
- Ownership Percentage Change: This transaction reduced Mountcastle's direct holdings by 5.24%, leaving him with 226,804 shares directly held, which represents a 0.18% stake in the company's outstanding shares, reflecting changes in ownership structure.
- Stable Financial Performance: Despite a 10.15% decline in PRVA stock in 2026, the company exceeded earnings expectations in its Q4 FY 2025 report, posting earnings of $0.07 per share, significantly above the $0.04 estimate, demonstrating resilience in its fundamentals.
- Customer Base Expansion: By acquiring an Accountable Care Organization (ACO), Privia gained approximately 1.5 million customers with medical plans such as Medicare, Medicare Advantage, and Medicaid, indicating growth potential in its value-based operations.
See More
